Loading...
Docoh

Seelos Therapeutics (SEEL)

News

From Benzinga Pro
Psychedelic Stock Gainers And Losers From July 1, 2022
1 Jul 22
Cannabis, Markets, Movers
GAINERS: Allied (OTC:ALID) shares closed up 4.17% at $0.50
Psychedelic Stock Gainers And Losers From June 30, 2022
30 Jun 22
Cannabis, Markets, Movers
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 4.44% at $10.82
Seelos Therapeutics, Numinus Wellness Among Top Psychedelic Movers Of Today
29 Jun 22
Cannabis, Markets, Movers
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 6.77% at $0.69
GH Research, Numinus Wellness Among Top Psychedelic Movers Of Today
28 Jun 22
Cannabis, Markets, Movers
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 3.03% at $0.85
Allied, Revive Therapeutics Among Top Psychedelic Movers Of Today
27 Jun 22
Cannabis, Markets, Movers
GAINERS: Field Trip Health (NASDAQ:FTRP) shares closed up 3.12% at $0.82
Allied, Revive Therapeutics Among Top Psychedelic Movers Of Today
24 Jun 22
Cannabis, Markets, Movers
GAINERS: Allied (OTC:ALID) shares closed up 29.44% at $0.56
Seelos Therapeutics, Compass Pathways Among Top Psychedelic Movers Of Today
23 Jun 22
Cannabis, Markets, Movers
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 6.63% at $0.71
Psychedelic Stock Gainers And Losers From June 22, 2022
22 Jun 22
Cannabis, Markets, Movers
GAINERS: ATAI Life Sciences (NASDAQ:ATAI) shares closed up 4.17% at $3.50
Revive Therapeutics, Numinus Wellness Among Top Psychedelic Movers Of Today
21 Jun 22
Cannabis, Markets, Movers
GAINERS: Revive Therapeutics (OTC:RVVTF) shares closed up 7.43% at $0.31
Psychedelic Stock Gainers And Losers From June 17, 2022
17 Jun 22
Cannabis, Markets, Movers
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 5.69% at $0.67
Psychedelic Stock Gainers And Losers From June 16, 2022
16 Jun 22
Cannabis, Markets, Movers
GAINERS: GH Research (NASDAQ:GHRS) shares closed up 3.08% at $10.05 LOSERS:
Psychedelic Stock Gainers And Losers From June 15, 2022
15 Jun 22
Cannabis, Markets, Movers
GAINERS: Cybin (AMEX:CYBN) shares closed up 9.11% at $0.62
Psychedelic Stock Gainers And Losers From June 14, 2022
14 Jun 22
Cannabis, Markets, Movers
GAINERS: Compass Pathways (NASDAQ:CMPS) shares closed up 9.90% at $9.44
ATAI Life Sciences, Compass Pathways Among Top Psychedelic Movers Of Today
13 Jun 22
Cannabis, Markets, Movers
GAINERS: Mind Medicine (NASDAQ:MNMD) shares closed up 1.06% at $0.81 LOSERS:
Psychedelic Stock Gainers And Losers From June 10, 2022
10 Jun 22
Cannabis, Markets, Movers
GAINERS: Cybin (AMEX:CYBN) shares closed up 6.16% at $0.67
Small Pharma, Cybin Among Top Psychedelic Movers Of Today
9 Jun 22
Cannabis, Markets, Movers
GAINERS: Small Pharma (OTC:DMTTF) shares closed up 12.55% at $0.13
12 Health Care Stocks Moving In Thursday's Pre-Market Session
9 Jun 22
Pre-Market Outlook, Markets, Movers
Seelos Therapeutics Announces Data Demonstrating Statistically Significant Downregulation Of mRNA And Reduction Of Alpha Synuclein In An In Vitro Gene Therapy Study If SLS-004 Utilizing CRISPR-dCas9 In Dementia With Lewy Bodies
9 Jun 22
Biotech, News, FDA, General
- A Single Dose of SLS-004 Produced 19% Downregulation of mRNA and ~40% Reduction of Alpha-Synuclein Compared to the Control Group - These Results Support Advancing SLS-004 into Additional Preclinical Studies in
Mind Medicine, Seelos Therapeutics Among Top Psychedelic Movers Of Today
8 Jun 22
Cannabis, Markets, Movers
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 7.70% at $0.78
Seelos Therapeutics, ATAI Life Sciences Among Top Psychedelic Movers Of Today
7 Jun 22
Cannabis, Markets, Movers
GAINERS: Seelos Therapeutics (NASDAQ:SEEL) shares closed up 9.47% at $0.72

Press releases

From Benzinga Pro
World's Richest Man Says Psychedelics Could Make a Real Difference in Mental Health
15 Jun 22
Small Cap, Opinion, Press Releases
FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, June 15, 2022 /PRNewswire/ -- Elon Musk believes that psychedelics and other plant-based drugs are better than pharma meds in treating a number of
Seelos Therapeutics Announces Data Demonstrating Statistically Significant Downregulation of mRNA and Reduction of Alpha Synuclein in an In Vitro Gene Therapy Study of SLS-004 Utilizing CRISPR-dCas9 in Dementia with Lewy Bodies
9 Jun 22
Press Releases
- A Single Dose of SLS-004 Produced 19% Downregulation of mRNA and ~40% Reduction of Alpha-Synuclein Compared to the Control Group - These Results Support Advancing SLS-004 into Additional Preclinical Studies in Dementia
Seelos Therapeutics Receives a Notice of Allowance in the U.S. for an Additional Patent for SLS-007
18 May 22
Press Releases
NEW YORK, May 18, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,
Seelos Therapeutics to Participate in the 2022 Jefferies Global Healthcare Conference
12 May 22
Entertainment, Press Releases, General
NEW YORK, May 12, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,
Oregon to Become the First State to Legally Roll Out Psilocybin
28 Apr 22
Small Cap, Opinion, Press Releases
FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK , April 28, 2022 /PRNewswire/ -- Oregon is set to become the first US state to market legal psilocybin, the psychoactive substance found in magic
Seelos Therapeutics to Participate in the B. Riley Securities' Virtual Neuro and Ophthalmology Conference
22 Apr 22
Press Releases
NEW YORK, April 22, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,
Why Psychedelics Could Soon Replace Antidepressants
13 Apr 22
Small Cap, Opinion, Press Releases
FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, April 13, 2022 /PRNewswire/ -- Anxiety disorders are the most common mental illness in the US, affecting approximately 40 million adults each year,
Seelos Therapeutics Announces Amendment of SLS-002 Agreement to Repurchase the Remaining Royalties Payable to Phoenixus AG for SLS-002 (Intranasal Racemic Ketamine Program), All Future Success and Commercial Based Milestones and the Change of Control Fee
11 Apr 22
Press Releases
NEW YORK, April 11, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (NASDAQ:SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases,